Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 1
2019 3
2020 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals.
Bonin CRB, Fernandes GC, de Menezes Martins R, Camacho LAB, Teixeira-Carvalho A, da Mota LMH, de Lima SMB, Campi-Azevedo AC, Martins-Filho OA, Dos Santos RW, Lobosco M; Collaborative Group for Studies of Yellow Fever Vaccine. Bonin CRB, et al. BMC Bioinformatics. 2020 Dec 14;21(Suppl 17):551. doi: 10.1186/s12859-020-03845-3. BMC Bioinformatics. 2020. PMID: 33308151 Free PMC article.
Duration of post-vaccination humoral immunity against yellow fever in children.
de Noronha TG, de Lourdes de Sousa Maia M, Geraldo Leite Ribeiro J, Campos Lemos JA, Maria Barbosa de Lima S, Martins-Filho OA, Campi-Azevedo AC, da Silva Freire M, de Menezes Martins R, Bastos Camacho LA; Collaborative Group for Studies of Yellow Fever Vaccine. de Noronha TG, et al. Vaccine. 2019 Nov 15;37(48):7147-7154. doi: 10.1016/j.vaccine.2019.09.051. Epub 2019 Oct 4. Vaccine. 2019. PMID: 31590934 Free article.
17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
Campi-Azevedo AC, Peruhype-Magalhāes V, Coelho-Dos-Reis JG, Antonelli LR, Costa-Pereira C, Speziali E, Reis LR, Lemos JA, Ribeiro JGL, Bastos Camacho LA, de Sousa Maia ML, Barbosa de Lima SM, Simões M, de Menezes Martins R, Homma A, Cota Malaquias LC, Tauil PL, Costa Vasconcelos PF, Martins Romano AP, Domingues CM, Teixeira-Carvalho A, Martins-Filho OA; Collaborative Group for Studies of Yellow Fever Vaccine. Campi-Azevedo AC, et al. Emerg Infect Dis. 2019 Aug;25(8):1511-1521. doi: 10.3201/eid2508.181432. Epub 2019 Aug 17. Emerg Infect Dis. 2019. PMID: 31298654 Free PMC article.
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine.
Abdala-Torres T, Campi-Azevedo AC, da Silva-Pereira RA, Dos Santos LI, Henriques PM, Costa-Rocha IA, Otta DA, Peruhype-Magalhães V, Teixeira-Carvalho A, Araújo MSS, Fernandes EG, Sato HK, Fantinato FFST, Domingues CMAS, Kallás EG, Tomiyama HTI, Lemos JAC, Coelho-Dos-Reis JG, de Lima SMB, Schwarcz WD, de Souza Azevedo A, Trindade GF, Ano Bom APD, da Silva AMV, Fernandes CB, Camacho LAB, de Sousa Maia ML; Collaborative Group for Studies of Yellow Fever Vaccine; Martins-Filho OA, do Antonelli LRDV. Abdala-Torres T, et al. NPJ Vaccines. 2024 Mar 8;9(1):54. doi: 10.1038/s41541-024-00836-w. NPJ Vaccines. 2024. PMID: 38459059 Free PMC article.
Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.
Ferreira CC, Campi-Azevedo AC, Peruhype-Magalhāes V, Coelho-Dos-Reis JG, Antonelli LRDV, Torres K, Freire LC, da Costa-Rocha IA, Oliveira ACV, Maia MLS, de Lima SMB, Domingues CM, Teixeira-Carvalho A, Martins-Filho OA, da Mota LMH; Collaborative Group for Studies of Yellow Fever Vaccine. Ferreira CC, et al. Arthritis Res Ther. 2019 Mar 14;21(1):75. doi: 10.1186/s13075-019-1854-6. Arthritis Res Ther. 2019. PMID: 30871593 Free PMC article. Clinical Trial.
Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
Campi-Azevedo AC, Peruhype-Magalhães V, Coelho-Dos-Reis JG, Costa-Pereira C, Yamamura AY, Lima SMB, Simões M, Campos FMF, de Castro Zacche Tonini A, Lemos EM, Brum RC, de Noronha TG, Freire MS, Maia MLS, Camacho LAB, Rios M, Chancey C, Romano A, Domingues CM, Teixeira-Carvalho A, Martins-Filho OA; Collaborative Group for Studies of Yellow Fever Vaccine. Campi-Azevedo AC, et al. J Immunol Methods. 2017 Sep;448:9-20. doi: 10.1016/j.jim.2017.05.002. Epub 2017 May 14. J Immunol Methods. 2017. PMID: 28514646
Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults.
Reis LR, Costa-Rocha IA, Abdala-Torres T, Campi-Azevedo AC, Peruhype-Magalhães V, Araújo MSS, Spezialli E, do Valle Antonelli LR, da Silva-Pereira RA, Almeida GG, Fernandes EG, Fantinato FFST, Domingues CMAS, Lemos MCF, Chieppe A, Lemos JAC, Coelho-Dos-Reis JG, de Lima SMB, de Souza Azevedo A, Schwarcz WD, Camacho LAB, de Lourdes de Sousa Maia M, de Noronha TG, Duault C, Rosenberg-Hasson Y, Teixeira-Carvalho A, Maecker HT, Martins-Filho OA; Collaborative Group for Studies of Yellow Fever Vaccine. Reis LR, et al. Sci Rep. 2024 Apr 2;14(1):7709. doi: 10.1038/s41598-024-57645-3. Sci Rep. 2024. PMID: 38565882 Free PMC article.